mTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer's disease

Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC and Butler PC: Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 53:474–481. 2004. View Article : Google Scholar : PubMed/NCBI

Moroz N, Tong M, Longato L, Xu H and de la Monte SM: Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis. 15:29–44. 2008.PubMed/NCBI

Bao CR, Zhou M and Qin DL: Present situation of studies about the relationship between type 2 diabetes and Alzheimer’s disease. J Luzhou Medical College. 32:568–569. 2009.(In Chinese).

Zhu XY, Niu BF, Dong ZX and Huang HY: Studies of the relationship between type 2 diabetes and Alzheimer’s disease. Medical Review. 17:1528–1531. 2011.

Chen YJ and Tian JZ: Alzheimer’s disease is another form of diabetes. Chin J Gerontology. 28:402–406. 2008.(In Chinese).

de la Monte SM and Wands JR: Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimer Disease. 7:45–61. 2005.PubMed/NCBI

Li Y: The awareness of the relationship between Central insulin resistance and Alzheimer’s disease. J Diagn Pract. 8:248–251. 2009.

Leibowitz G, Cerasi E and Ketzinel-Gilad M: The role of mTOR in the adaptation and failure of beta-cells in type 2 diabetes. Diabetes. 10(Suppl 4): 157–169. 2008.PubMed/NCBI

Glynn EL, Lujan HL, Kramer VJ, Drummond MJ, DiCarlo SE and Rasmussen BB: A chronic increase in physical activity inhibits fed-state mTOR/S6K1 signaling and reduces IRS-1 serine phosphorylation in rat skeletal muscle. Appl Physiol Nutr Metab. 33:93–101. 2008. View Article : Google Scholar : PubMed/NCBI

Vila-Bedmar R, Lorenzo M and Fernández-Veledo S: Adenosine 5′-monophosphate-activated protein kinase-mammalian target of rapamycin cross talk regulates brown adipocyte differ- entiation. Endocrinology. 151:980–992. 2010.

Zhang C, Yoon MS and Chen J: Amino acid-sensing mTOR signaling is involved in modulation of lipolysis by chronic insulin treatment in adipocytes. Am J Physiol Endocrinol Metab. 296:E862–E868. 2009. View Article : Google Scholar : PubMed/NCBI

Fan H: The research progress of risk-related between diabetes and Alzheimer’s disease. J Practical Geriatrics. 24:342–345. 2010.

Mi K and Johnson GV: The role of Tau phosphorylation in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 3:449–463. 2006.

An WL, Cowburn RF, Li L, et al: Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease. Am J Pathol. 163:591–607. 2003.PubMed/NCBI

Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM and Feany MB: TOR-mediated cell-cyele activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol. 16:230–241. 2006. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Zhang Sl, Gao FH, Chen Y and Yang XJ: The research of GSK-3β and tau phosphorylated proteins in hippocampal tissue of type 2 diabetes and Alzheimer’s disease rats. Chin J Gerontol. 29:63–66. 2010.(In Chinese).